<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04133584</url>
  </required_header>
  <id_info>
    <org_study_id>ZJCDC20190918</org_study_id>
    <nct_id>NCT04133584</nct_id>
  </id_info>
  <brief_title>The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine</brief_title>
  <official_title>Multiple Centers, Randomized, and Control Trail on the Immunogenicity and Safety of the Simultaneously Vaccination of Inactivated Enterovirus 71 Vaccine (EV71) and Seasonal Influenza Vaccine(SIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Provincial Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Provincial Center for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Immunogenicity and safety of the simultaneously&#xD;
      vaccination of Inactivated Enterovirus 71 Vaccine (EV71) and seasonal influenza vaccine(SIV)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main subjects:&#xD;
&#xD;
      The seroconversion rate for each antigen when EV71 is administrated with SIV&#xD;
&#xD;
      Secondary subjects:&#xD;
&#xD;
      The positive rate of antibody for each antigen when EV71 is administrated with SIV The safety&#xD;
      for each antigen when EV71 is administrated with SIV&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>immunogenicity evaluation</measure>
    <time_frame>change from baseline antibody concentration at 28 days after the last dose</time_frame>
    <description>The positive rate of antibody</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety evaluation: The occurrence of adverse events</measure>
    <time_frame>up to 30 days after every injection</time_frame>
    <description>The occurrence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1134</enrollment>
  <condition>Seasonal Influenza</condition>
  <condition>Hand, Foot and Mouth Disease</condition>
  <arm_group>
    <arm_group_label>Group 1 EV71 +SIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give 2 doses of Inactivated Enterovirus 71 Vaccine (EV71) and seasonal influenza vaccine(SIV) simultaneously with 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 EV71</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Give 2 doses of Inactivated Enterovirus 71 Vaccine (EV71) with 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 SIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Give 2 doses of seasonal influenza vaccine(SIV) simultaneously with 28 days apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 +SIV</intervention_name>
    <description>Give 2 doses of EV71 +SIV, get 2 blood samples before the first dose and 28-43 days after the last dose.</description>
    <arm_group_label>Group 1 EV71 +SIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71</intervention_name>
    <description>Give 2 doses of EV71 , get 2 blood samples before the first dose and 28-43 days after the last</description>
    <arm_group_label>Group 2 EV71</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SIV</intervention_name>
    <description>Give 2 doses of SIV , get 2 blood samples before the first dose and 28-43 days after the last</description>
    <arm_group_label>Group 3 SIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parent/legal acceptable representative is willing and able to understand the protocol&#xD;
             requirements and provide informed consent.&#xD;
&#xD;
          -  Participant is aged ≥ 6 month to &lt;12 months.&#xD;
&#xD;
          -  Participant without preventive inoculation of Enterovirus 71 Vaccine ,seasonal&#xD;
             influenza vaccine vaccine and previous history of Enterovirus.&#xD;
&#xD;
          -  Subject and parent/guardian able to attend all scheduled visits and comply with all&#xD;
             trial procedures.&#xD;
&#xD;
          -  Body temperature ≤ 37.0#.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to any constituent of the vaccine.&#xD;
&#xD;
               -  Known acute illness, severe chronic disease, acute exacerbation of chronic&#xD;
                  disease and fever.&#xD;
&#xD;
               -  Known or suspected impairment of immunologic function, or receipt of&#xD;
                  immunosuppressive therapy or immunoglobulin since birth.&#xD;
&#xD;
               -  Reported the history of allergies, convulsions, epilepsy, mental illness and&#xD;
                  brain disease and clear serious systemic reaction.&#xD;
&#xD;
               -  Known bleeding disorder.&#xD;
&#xD;
               -  Receipt of the whole blood, blood plasma or immunoglobulin before the trial&#xD;
                  vaccination.&#xD;
&#xD;
               -  Reported the history of acute illness had need systemic antibiotics or antiviral&#xD;
                  treatment of infections in the 7 days preceding the trial vaccination.&#xD;
&#xD;
               -  An acute illness with or without fever (temperature ≥ 38.0#) in the 3 days&#xD;
                  preceding enrollment in the trial.&#xD;
&#xD;
               -  Participation in any other intervention clinical trial.&#xD;
&#xD;
               -  Any condition which, in the opinion of the investigator, would pose a health risk&#xD;
                  to the subject or interfere with the vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>11 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Liandu Center for Disease Control and Prevention</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Enterovirus 71 Vaccine</keyword>
  <keyword>seasonal influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Enterovirus Infections</mesh_term>
    <mesh_term>Foot-and-Mouth Disease</mesh_term>
    <mesh_term>Hand, Foot and Mouth Disease</mesh_term>
    <mesh_term>Mouth Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

